{"name":"Aligos Therapeutics","slug":"aligos-therapeutics","ticker":"","exchange":"","domain":"aligos.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":2186000,"revenueGrowth":-39.5,"grossMargin":0,"rdSpend":69453000,"netIncome":-24193000,"cash":88533000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"date":"2026-03-05","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxPQmVHMVRLdHBuRTktb1RPaU9kZzE3cVZuNWdmNDdXWlczTU9hRFFuQWNNa2txT213VlJhTkxUSE5NYlZDWEVqcUxFT2NZQUFBb08xZ2VzaURLSHBnNEM0WXRJLUl4V09BaWFUZjF3RzVBSWF6cW90N2hiaE42WWpHRlFn?oc=5","date":"2026-02-27","type":"pipeline","source":"Pharmaceutical Online","summary":"9 Pharma Trends To Watch In 2026 - Pharmaceutical Online","headline":"9 Pharma Trends To Watch In 2026","sentiment":"neutral"},{"date":"2026-02-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOZGd4azZYTnVsNEFlMUowRERLamloYzFOdkRvSHhaTS1MbHNRbXhVRnZHTVBFR0R2VXg3T21jZE9mTFhTTE90clRsOHdyVGIwUl9zRFNfU3BPZVFHLWQyRGZ2RmdkNDZNdmRoeFAtNEVTbGhmNWlTVkdwM0hGYTk1ekhTUmp5MDNoVjQ4SGUxWWpmbkUzajFTR0JtQQ?oc=5","date":"2026-01-13","type":"pipeline","source":"Yahoo Finance","summary":"Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer - Yahoo Finance","headline":"Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxQYXFGTDZYMWZiQjg2TnBiZXNaWGFLb3gyRmhpNHEtaXZEX3pNak9GTXJuU1JqcDBRamJxSlJfU2ZnWkE3QnR0VEpFWkhESVVOZGRDcWgwWU5tYy1nUks3eUhENExXWGZoOFhGbmU5aHBmRnBDVy1jbG9KUGJmdWxKXzJub3BkQzNXY0k1RzFLLUU5eU9lN3lFSzFSNmpsY0U2TjZfU0ZrdURuVFM2dUU5eWlMYmN5SUJWQlE?oc=5","date":"2026-01-13","type":"pipeline","source":"stocktitan.net","summary":"Global drug launch veteran to build hepatitis B commercial team at Aligos - stocktitan.net","headline":"Global drug launch veteran to build hepatitis B commercial team at Aligos","sentiment":"neutral"},{"date":"2025-11-06","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxPME5tNHpSbG41YUMydmg3OTlBZ3diMUxsd2Q0ZXB1VXZkcFFieE1NYzcxWFBPWk9HLUVOaDBsNUVDUmhia3I5aWR2QkVaaUVCSzY5cGszNFVNMlc4M05RNF9hWEx5M21ZNm1QN196OGhOcng3ZFU1Wm5LMDhZeXhFaA?oc=5","date":"2025-09-15","type":"pipeline","source":"Pharmaceutical Executive","summary":"Lawrence M. Blatt on Taking the Leap from Scientist to Founder - Pharmaceutical Executive","headline":"Lawrence M. Blatt on Taking the Leap from Scientist to Founder","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOXzU1WGxLWERXWTZ6VUdQZHdQZW1kcG53OHNkQ2FKX2RWZ0xuTEw1bkhZR3FzUzZvZVNXUmUxRVBjY054Q1QySGhXa29Qc1BQX1dwczcxdkRjbnlqajJScXJfdWU2SEhjWHdVQ0NRWG9FWFVmdWlWTXFzUXBYS2w4dVF3ZFJDWk5hUnk5VVpnQUlzRlhBdjB6Y0NIVlE?oc=5","date":"2025-08-22","type":"pipeline","source":"Fierce Biotech","summary":"Career oncologist makes Big Pharma leap to BMS—Chutes & Ladders - Fierce Biotech","headline":"Career oncologist makes Big Pharma leap to BMS—Chutes & Ladders","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxQT3Jva2kzcUc4Um9FSkd6QkJnTlJDT1lGaVc4YjNsbUhBMHJoaEYzbFliZllDVTY5N0RRSkVyM0xxWXFJeWc1RWRyOFVrRVIxN2N1anBDVi1VVVZNYzVzSUhaVW1tWHVvSFRWU0JfaEtabGZ2Mm9uMEp2Q0RUOTk2NGlfRkZYd3JXcnA3VWN5WFdjTDB3TUJGc3h0RlpkWDNiQ09jN2F6dlF0MXM1THN4WWsyMDhZcWQtTlRqc2VmM0Z4cEd5Szh2aE1BTXRJSUE4NWNsRWFGNHJFUF9JT3Z1TVROQnREZXZYeDlmc1lrblNRZXZwT2VTY1FuM2M5SHdsV1BjM0d3?oc=5","date":"2025-08-20","type":"regulatory","source":"Investing News Network","summary":"Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs - Investing News Network","headline":"Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head","sentiment":"neutral"},{"date":"2025-08-06","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-08-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxNY1JaSEFaVnFfU1RFUF85NFdPTWVkNWpVR1V5dXIxSnZiUGZZV0w2andLOEdNSXUza3FUbnl2N1dQZThDYTZ0eXV0a2V3c1JSMjJqek5aNzd1MGY1M1JkNmZreDJ3cWpRTXR4aWZTLXF1cEowS0xoMnJla3NSd1BReEhORDNmRmI5U1djd3lwNDB0UG5kM0ZzMmNxXzJpSE9YNXRyWnVuOFVDb09Ocld3djFIZF9qd2RweUNPeE5xWlVxWlZUdXUwMGlKdUg5NXVsa1E?oc=5","date":"2025-07-30","type":"pipeline","source":"PR Newswire","summary":"THR-β Agonist Market on the Rise: Insights and Projections Upto 2034 | DelveInsight - PR Newswire","headline":"THR-β Agonist Market on the Rise: Insights and Projections Upto 2034 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxOT05BUl8zUHdqQVFKbXJDRURMSUJoeDlIYzQ0QnRpQ0NZRDRZVHdQTHMybW5IMHlMZE53akxCM2x2ZWFkS1kxdTR6NHJmNHNkUENmdzhSVFdETzA0MTZQT19HWlVZTmxFU1dydlF2MHh3ZGNYNG5iTkRoMnY0X1M1SEJTcWNNV2VUTTZxckZsaVNja0g0RVp3MzVuVlpTSkMyWWtmR0NaZFpIWDll?oc=5","date":"2024-12-11","type":"pipeline","source":"Seeking Alpha","summary":"Aligos Therapeutics: Promising Pipeline With Cash And Dilution Risks (NASDAQ:ALGS) - Seeking Alpha","headline":"Aligos Therapeutics: Promising Pipeline With Cash And Dilution Risks (NASDAQ:ALGS)","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":2186000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":2186000,"period":"2025-12-31"},{"value":3611000,"period":"2024-12-31"},{"value":3611000,"period":"2024-12-31"},{"value":6191000,"period":"2023-12-31"},{"value":6191000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":69453000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-24193000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":88533000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}